Identification of the first antagonist peptide that inhibits biological effects of interleukin-15

Alicia Santos¹, Osvaldo Reyes¹, Ania Cabrales¹, Yunier Rodriguez¹, Haydee Geronimo¹, Hilda E Garay¹, Celia A Arrieta¹, Miriam Ojeda¹, Ana C Machado¹, José Suarez¹, Julio A Ancisar¹, Mariela Vázquez¹, Gerardo Guillén¹, Araceli Chico², Miguel Estévez², Alexey Llopiz³, Jesús Noda³, Aniel Sánchez³, Lorenzo Silengo³, Fiorella Altruda³, Silvio Perea¹

ABSTRACT

Interleukin-15 (IL-15) is a pro-inflammatory cytokine that is expressed in several autoimmune and inflammatory diseases. We have identified the 36-45 sequence KVTAMKCFLL on human IL-15 that is recognized by a soluble form of recombinant hIL-15Rα-Fc fusion protein. This sequence synthesized as a 10 aa. peptide binds to the IL-15Rα and was able to block the biological activity of IL-15 in two IL-15 dependent cell lines. Using alanine scan strategy we identified a more active peptide by replacing the second Lys in the sequence for the polar non-charged amino acid threonine. Moreover, soluble IL-15Rα was quantitated by a newly developed enzyme-linked immunosorbent assay (ELISA) using the P8 peptide as capture in samples of synovial fluid from patients with rheumatoid arthritis (RA) and osteoarthritis (OA). This research won the 2012 Award of the Cuban National Academy of Sciences.

Keywords: antagonist, cytokine, IL-15, peptide, alpha receptor

Introduction

The development of biologic agents, that selectively block the effects of pro-inflammatory cytokines, has provided a major advance in the treatment of Rheumatoid arthritis (RA). This is a chronic autoimmune disease which affects 1 % of the population and is associated with significant morbidity and increased mortality. Imbalances in pro- and anti-inflammatory cytokines promote induction of autoimmunity, inflammation and joint destruction in RA [1]. Currently available TNF-α and IL-6 targeting biologic agents are highly effective. However, about 40 % of RA patients who receive a TNF inhibitor fail to achieve an adequate response and other patients discontinue TNF-blocking agents within the first year of treatment [2]. Therefore, other cytokines are being tested as targets in the clinic with promising results [3, 4].

IL-15 is a proinflammatory cytokine associated with several autoimmune diseases, particularly RA [5, 6]. Soluble IL-15 has been detected in synovia of patients with RA mainly expressed by macrophages, fibroblasts, and endothelial cells [7, 8], and there it recruits circulating memory T cells in the synovial membrane and may up regulate TNF-α, IL-17, and other pro-inflammatory cytokines [9-11]. Moreover, soluble IL-15 appears to be an important contributor to osteoclastogenesis contributing to bone erosion [12, 13]. Other two functional forms of IL-15 have been identified: IL-15Rα-independent membrane-bound IL-15 [14, 15] and membrane IL-15 anchored through IL-15Rα [16], although they have been less studied in RA.

Several studies have generated different IL-15 antagonists, such as neutralizing antibodies directed against IL-15 itself or alternatively, against IL-2R/IL-15Rβ, mutant IL-15 molecules, and soluble fragments of the IL-15Rα chain linked to the immunoglobulin Fc element, that have been shown to be effective both in animal models and humans [17-19].

We focused on animal studies finding an antagonist of IL-15/IL-15Rα binding because IL-15Rα is a specific IL-15 subunit receptor that plays an important role in different mechanisms of action described for IL-15.

¹ Centro de Ingeniería Genética y Biotecnología, CIGB Ave. 31 e/ 158 y 190, Cubancán, Playa, CP 11600, La Habana, Cuba ²Hospital Clínico Quirúrgico Hermanos Ameijeiras, La Habana, Cuba ³ University of Torino, Italy

Corresponding author

Alicia Santos1, Osvaldo Reyes1, Ania Cabrales1, Yunier Rodriguez1, Haydee Geronimo1, Hilda E Garay1, Celia A Arrieta1, Miriam Ojeda1, Ana C Machado1, José Suarez1, Julio A Ancisar1, Mariela Vázquez1, Gerardo Guillén1, Araceli Chico2, Miguel Estévez2, Alexey Llopiz3, Jesús Noda3, Aniel Sánchez3, Lorenzo Silengo3, Fiorella Altruda3, Silvio Perea1

RESEARCH
and it has been shown that the IL-15/IL-15Rα complex is more active than IL-15 alone [20, 21]. We have identified a small peptide corresponding to the sequence 36-45 of IL-15 (KVVTAMKCFLLL) named P8, which specifically binds to IL-15Rα and exhibits an antagonist effect on IL-15 activity [22].

Moreover, we prepared a series of single points, Ala-substituted P8 peptide analogs to evaluate contribution of their individual amino acid side chains to IL-15Rα binding. As a result, we have identified the peptide [K6T]P8 exhibiting a ten-fold enhanced antagonist activity. Both wild type P8 and this more active analog [K6T]P8 inhibit secretion of TNF-α, a validated target in RA [23]. Finally, we used P8 peptide in immunoassays to determine the presence of soluble IL-15Rα in synovial fluid and its potential role in inducing reverse signaling through membrane-bound IL-15 on cells from synovial fluid. Interestingly, we found higher levels of IL-15Rα in RA compared with osteoarthritis (OA), and also we found that there is a positive relationship between these high levels of IL-15Rα and high levels of IL-6 in RA but not in OA [24].

**Results**

Identification of a binding sequence to IL-15Rα

The peptide spot synthesis approach was used to identify regions of IL-15 involved in the binding to IL-15Rα. The cellulose sheets displays 22 peptides that comprise entire human IL-15 sequence were incubated with IL-15Rα-Fc to Fc of human IgG1. We observed a strong signal on spot 8 corresponding to the 36-45 sequence KVVTAMKCFLLL on mature IL-15 [22]. No positive spots were observed when cellulose was incubated with human antibody IgG1, ruling out the possibility that IL-15Rα-Fc occurred on binding through its Fc region.

P8 competitively inhibits the binding of IL-15 to IL-15Rα and IL-15 biological activity

Competitive ELISA was performed to test the binding specificity of the P8 peptide to IL-15Rα. The sequence corresponding to spot 8 (KVVTAMKCFLLL) was synthesized as a soluble linear 10 aa pepptide. IL-15Rα-Fc and different concentrations of P8 peptide were co-incubated with IL-15 immobilized in the plate and the bound IL-15-Rα-Fc was detected with HRP-conjugated goat anti-human IgG or with an antibody anti-IL-15Rα development in goat; and later incubated with HRP-conjugated mouse anti-goat IgG. Both immunoassays showed similar results. As shown in figure 1, the P8 peptide displaces the binding of IL-15Rα to hIL-15 in a dose-dependent manner.

Biological activity of P8 peptide was tested for its ability to inhibit IL-15 activation of cell proliferation of two IL-15 dependent cell lines: the murine CTL2 cell line and the human KiT225 cell line that expresses the trimeric receptor IL-15Rαβγ. The P8 peptide inhibited IL-15-induced proliferation in a dose-dependent manner at plateau concentrations of 300 pg/mL of IL-15 in the KiT225 human leukemia cell line, showing a 50 % inhibitory concentration (IC50) of 130 μM (Figure 2). The inhibitory effect of the P8 peptide was also dependent on IL-15 concentration in the CTLL-2 cell line and the P8 peptide alone was unable to affect the proliferation of these cells induced by IL-2 [23].

Therefore, with the aim to study the contribution of each amino acid to the antagonist effect of P8 peptide and reduce its IC50 (130 μM), we synthesized a family of single Ala mutants of this peptide. Then, they were evaluated by preincubation with IL-15-Rα-Fc, and subsequently, the resulting mixtures were added onto IL-15-coated surfaces in order to measure the ability of each synthetic peptide to competitively inhibit IL-15/IL-15Rα complex formation. We found that Phe and Cys are important for peptide binding to IL-15Rα. Other single point mutations were investigated and the second Lys in the sequence was replaced by the polar non-charged amino acid threonine. Interestingly, we found that the replacement of Lys41 by Thr generated a small peptide corresponding to the sequence KVTAMKCFLLL which specifically binds to IL-15Rα.

In order to assess activity of P8 and its analog [K6T]P8 on other IL-15-induced biological effects, we measured the effect of these peptides on TNF-α secretion. Synovial cells from RA patients with high levels of IL-15 in synovial fluids were incubated with P8 and the mutant [K6T]P8 in the presence of IL-15 for 72 h, and then, TNF-α levels were determined by preincubation with IL-15Rα-Fc. As shown in figure 1, P8 peptide displaces the binding of IL-15Rα to hIL-15 in a dose-dependent manner.
by ELISA. We found that both peptides inhibited TNF-α secretion from a pool of synovial cells and, in agreement with previous results obtained for IL-15-dependent cell lines, [K6T]P8 was more inhibitory on TNF-α secretion than the P8 peptide (Figure 3).

**Usefulness of P8 peptide as a tool for detecting IL-15Ra**

We used the P8 peptide as capture to measure the IL-15Ra level in synovial fluid from patients with RA (n = 18) or OA (n = 17) using our previously developed ELISA [16]. Soluble IL-15Ra (sIL-15Ra) was detected in 100 % of RA patients (18/18) and in 82.3 % of OA patients (14/17). That was the first report on detecting sIL-15Ra in synovial fluid. A significant increase in concentrations of sIL-15Ra was observed in synovial fluid collected from RA patients compared to those from OA patients (Figure 1 in reference [24]).

**Relevance of the study**

The first antagonist peptide described for IL-15 which specifically binds to IL-15Rs subunit and inhibits cell proliferation and proinflammatory cytokine secretion induced by IL-15 was obtained in this work. The strategy described summarizes the identification, assessing of its biological activities and its capacity as a tool to detect IL-15Ra. Therefore, this peptide is a potential drug as blocker of IL-15 in diseases such as RA, and can be used as immunoreagent to detect IL-15Ra in biological fluids. These results have two patents granted.

**Acknowledgements**

We thank the following collaborators of the CIGB for their contribution to this work: Karelia Cosme, Noraylis Lorenzo, Dagmara Pichardo, Sonia González and Yordanka Masforrol.